mammaprint dna microarray-based test for prognosis of her2þ early breast cancers (Agendia BV)
90
Structured Review
Agendia BV
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers
Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+microarray-based+breast+cancer+prognosis+test+mammaprint/mammaprint+dna+microarray+based+test+for+prognosis+of+her2%C3%BE+early+breast+cancers/pm20346697-199-14-13
Average 90 stars, based on 1 article reviews
Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+microarray-based+breast+cancer+prognosis+test+mammaprint/mammaprint+dna+microarray+based+test+for+prognosis+of+her2%C3%BE+early+breast+cancers/pm20346697-199-14-13
Average 90 stars, based on 1 article reviews
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Diagnostic devices as biomaterials: a review of nucleic acid and protein microarray surface performance issues. Article Snippet: This review of current DNA and protein microarray diagnostic and bio-analytical technologies focuses on the different surface chemistries used in these miniaturized surface-capture formats.. Description of current strategies in bio-immobilization and coupling to create multiplexed affinity bioassays in micrometer-sized printed spots, problems with current formats and review of some detection methods are included.. Recommendations for improving long-standing challenges in DNAand protein-based arrays are forwarded. |